Connect with us

Technology

Precision Optics Reports Second Quarter Fiscal Year 2024 Financial Results

Published

on

Conference Call Scheduled for today, February 14, 2024, at 5:00pm ET.

GARDNER, Mass., Feb. 14, 2024 /PRNewswire/ — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year 2024 for the period ended December 31, 2023.

Q2 2024 Financial Highlights (3 Months Ended December 31, 2023):

Revenue decreased 18% to $4.8 million, compared to $5.9 million in the same quarter of the previous fiscal year, but up 12% from the most recent sequential quarter. The year ago second quarter included a one-time sale of $600,000 of technology rights relating to a single-use medical device developed for a customer.Engineering revenue increased 33% to $2.3 million compared to $1.7 million in the same quarter of the previous fiscal year, and up 19% from the most recent sequential quarter.Production revenue was $2.6 million compared to $3.6 million in the same quarter of the previous fiscal year, and $2.4 million in the most recent sequential quarter.Gross margins were 30.1% compared to 44.2% in the same quarter of the previous year. Removing the impact of the technology rights revenue, gross margins a year ago would have been 37.8%.Net loss for the quarter was ($758,802), compared to a net income of $508,668 in the same quarter of the previous year. Adjusted EBITDA was ($269,034) for the quarter compared to $866,450 in the same quarter of the previous year. 

Recent Additional Highlights:

In November 2023, the Company announced the receipt of initial purchase orders towards a $1.4 million total program development project to develop a highly complex imaging sub-assembly for a next generation ophthalmoscope for one of the world’s largest technology-focused medical device companies.In December 2023, the Company announced the signing of a production and technology license agreement with a leading surgical robotics company to supply a single-use endoscope assembly used in their cystoscopy robotic surgery system.

Precision Optics’ CEO, Joseph Forkey, commented, “The Company’s results for Q2 were generally in-line with our expectations and consistent with what we have communicated previously.  While revenue was lower compared to last year due to timing differences between reorders for ongoing production, the exit of certain mature customer programs and the introduction of new customer programs, we have begun to see the rebound we expected with two new programs moving to production in the quarter and another restarting after a pandemic-related hold.  These programs contributed to a 6% quarter-over-quarter increase in production revenue, which, combined with record engineering revenue led to a 12% increase in total revenue compared to the first quarter.  Margins for the second quarter were lower than the first quarter, due to a differing sales mix, lower than normal production yields on certain programs starting or re-starting production as well as other one-time charges.  We believe these margin issues are transient and will be substantially resolved in the second half of the year, with gross margins returning to historical levels.

Dr. Forkey continued, “The growth we expect in the second half of fiscal 2024 is supported by the strength of our engineering pipeline, a leading indicator of future production volumes.  Engineering revenue was $2.3 million during the second quarter – a new quarterly record, up 33% year-over-year, and up 19% sequentially. We anticipate volumes from production orders coming on-line to lift our overall revenue to new quarterly record run-rates in this fiscal year.  Precision Optics’ core competencies — micro-optics, digital imaging, 3D endoscopy, and single-use medical devices — uniquely position us at the center of market segments that are significantly outpacing the growth of the broader medical device and defense / aerospace industries, providing us with an ongoing opportunity to significantly grow into the future. I look forward to an exciting second half of fiscal 2024.”

The following table summarizes the second quarter and fiscal year to date (unaudited) results for the periods ended December 31, 2023, and 2022:

Three Months

Six Months

Ended December 31,

Ended December 31,

2023

2022

2023

2022

Revenues

$4,824,289

$5,886,961

$9,145,544

$10,972,262

Gross Profit

1,450,976

2,599,472

2,914,587

4,238,913

Stock Compensation Expenses

382,431

108,746

491,177

319,776

Other

1,772,707

1,919,661

3,532,865

3,449,874

Total Operating Expenses

2,155,138

2,028,407

4,024,042

3,769,650

Operating Income (Loss)

(704,162)

571,065

(1,109,455)

469,263

Net Income (Loss)

(758,802)

(508,668)

(1,223,217)

349,944

Income (Loss) per Share

Basic

$          (0.13)

$          (0.09)

$          (0.20)

$               0.06

Fully Diluted

$          (0.13)

$          (0.09)

$          (0.20)

$               0.06

Weighted Average Common Shares Outstanding

Basic

6,066,572

5,638,302

6,066,545

5,638,302

Fully Diluted

6,066,572

5,935,911

6,066,545

5,937,471

Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented.

Conference Call Details
Date and Time: Wednesday, February 14, 2024, at 5:00pm ET

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/5l19x2DzRKG.

Replay: A teleconference replay of the call will be available until February 21, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 9304851. A webcast replay will be available at https://app.webinar.net/5l19x2DzRKG.  

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and  imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture.  Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division’s electronic imaging expertise and its Ross Optical division’s high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions to meet the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation, restructuring and other acquisition-related items.

This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous risk factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

December 31,

June 30,

2023

2023

ASSETS

Current Assets:

Cash and cash equivalents

$

987,044

$

2,925,852

Accounts receivable, net of allowance for doubtful accounts of $731,256
     at December 31, 2023 and $606,715 at June 30, 2023

3,511,544

3,907,407

Inventories

3,099,986

2,776,216

Prepaid expenses

234,121

249,681

Total current assets

7,832,695

9,859,156

Fixed Assets:

Machinery and equipment

3,253,746

3,227,481

Leasehold improvements

832,305

825,752

Furniture and fixtures

362,287

242,865

Total fixed assets

4,448,338

4,296,098

Less—Accumulated depreciation and amortization

3,966,839

3,862,578

Net fixed assets

481,499

433,520

Operating lease right-to-use asset

275,329

358,437

Patents, net

283,643

265,111

Goodwill

8,824,210

8,824,210

TOTAL ASSETS

$

17,697,376

$

19,740,434

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Current portion of capital lease obligation

$

44,519

$

43,209

Current maturities of long-term debt

513,259

513,259

Accounts payable

1,675,742

2,432,264

Customer advances

1,158,242

1,174,690

Accrued compensation and other

747,793

927,521

Operating lease liability

173,503

168,677

Total current liabilities

4,313,058

5,259,620

Capital lease obligation, net of current portion

45,890

68,482

Long-term debt, net of current maturities and debt issuance costs

1,919,350

2,175,980

Operating lease liability, net of current portion

101,826

189,760

Stockholders’ Equity:

Common stock, $0.01 par value: 50,000,000 shares authorized; issued and
     outstanding – 6,067,518 shares at December 31, 2023 and 6,066,518 at June 30, 2023

60,675

60,665

Additional paid-in capital

60,718,801

60,224,934

Accumulated deficit

(49,462,224)

(48,239,007)

Total stockholders’ equity

11,317,252

12,046,592

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

17,697,376

$

19,740,434

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE SIX MONTHS ENDED

DECEMBER 31, 2023 AND 2022

(UNAUDITED)

Three Months
Ended December 31,

Six Months
Ended December 31,

2023

2022

2023

2022

Revenues

$

4,824,289

$

5,886,961

$

9,145,544

$

10,972,262

Cost of Goods Sold

3,373,313

3,287,489

6,230,957

6,733,349

Gross Profit

1,450,976

2,599,472

2,914,587

4,238,913

Research and Development Expenses

221,728

155,264

434,486

365,891

Selling, General and Administrative
Expenses

1,933,410

1,873,143

3,589,556

3,403,759

Total Operating Expenses

2,155,138

2,028,407

4,024,042

3,769,650

Operating Income (Loss)

(704,162)

571,065

(1,109,455)

469,263

Interest Expense

(54,640)

(62,397)

(113,762)

(119,319)

Net Income (Loss)

$

(758,802)

$

508,668

$

(1,223,217)

$

349,944

Loss Per Share:

Basic

(0.13)

$

0.09

(0.20)

$

0.06

Fully Diluted

$

(0.13)

$

0.09

$

(0.20)

$

0.06

Weighted Average Common Shares
Outstanding:

Basic

6,066,572

5,638,302

6,066,545

5,638,302

Fully Diluted

6,066,572

5,935,911

6,066,545

5,937,471

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED

DECEMBER 31, 2023 AND 2022

(UNAUDITED)

Six Months
Ended December 31,

2023

2022

Cash Flows from Operating Activities:

Net Income (Loss)

$

(1,223,217)

$

349,944

Adjustments to reconcile net loss to net cash used in by operating activities –

Depreciation and amortization

104,261

104,750

Stock-based compensation expense

491,177

319,776

Non-cash interest expense

8,752

16,966

Changes in operating assets and liabilities –

Accounts receivable, net

395,863

(1,368,650)

Inventories, net

(323,770)

232,963

Prepaid expenses

15,560

271

Accounts payable

(756,522)

216,060

Customer advances

(16,448)

(110,132)

Accrued compensation and other

(188,480)

255,162

Net cash (used in) provided by operating activities

(1,492,824)

17,110

Cash Flows from Investing Activities:

Purchases of fixed assets

(152,240)

(13,583)

Additional patent costs

(18,532)

(24,054)

Net cash used in investing activities

(170,772)

(37,637)

Cash Flows from Financing Activities:

Payments of capital lease obligations

(21,282)

(20,049)

Payments of long-term debt

(256,630)

(183,855)

Gross proceeds from the exercise of stock options

2,700

Net cash used in financing activities

(275,212)

(203,904)

Net (decrease) increase in cash and cash equivalents

(1,938,808)

(224,431)

Cash and cash equivalents, beginning of period

2,925,852

605,749

Cash and cash equivalents, end of period

$

987,044

$

381,318

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA

Three Months

Six Months

Ended December 31,

Ended December 31,

2023

2022

2023

2022

Net Income (loss) (GAAP)

$

(758,802)

$

508,668

$

(1,223,217.00)

$

349,944

Stock based compensation

382,431

244,786

491,177.00

319,776

Depreciation and Amortization

52,697

52,667

104,261.00

105,078

Interest expense

54,640

60,329

113,762.00

117,251

Adjusted EBITDA (non-GAAP)

$

(269,034)

$

866,450

$

(514,017)

$

892,049

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-optics-reports-second-quarter-fiscal-year-2024-financial-results-302062206.html

SOURCE Precision Optics Corporation

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Nanalysis Announces Board Transition and Appointment of Three New Directors

Published

on

By

CALGARY, AB, May 1, 2026 /CNW/ – Nanalysis Scientific Corp. (the “Company”, TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, is pleased to announce the appointment of Jonathan Ladd, Werner Maas, and Steve Feick to its Board of Directors effective May 1, 2026.

Mr. Ladd is an experienced technology executive and former Chief Executive Officer of NovAtel Inc., a Nasdaq-listed GPS technology company acquired by Hexagon AB. He has a track record of scaling global technology businesses and brings extensive experience in capital markets, corporate governance, and strategic execution within advanced technology companies. He currently serves on the following boards: Takemetoit Inc., AgriRobot, Litus Inc., and is an advisor at Tall Grass Ventures. Mr. Ladd earned a bachelor’s degree with distinction in engineering and is a member of Tau Beta Pi National Engineering Honor Society.

Dr. Maas is a senior executive in the analytical instrumentation sector, having previously served as President of Bruker BioSpin Corporation and currently serving as Chief Executive Officer of Hudson Lab Automation. He brings deep expertise in nuclear magnetic resonance (NMR) technologies, as well as global sales, marketing, and commercialization of scientific instrumentation. Dr. Maas holds a Ph.D. in Chemistry from Radboud University in The Netherlands, as well as several executive management designations from the MIT Sloan School of Management.

Mr. Feick is President of Manvest Inc., part of the Mancal Group. He has a track record of developing and growing a portfolio of investments in agriculture, finance, supply chain, infrastructure technology, energy efficiency, and data analytics. As a former entrepreneur, he ensures that his operational and investor experience elevates the growth of the portfolio. He is an experienced investor and brings expertise in capital allocation, governance, and long-term strategic planning across private and public market investments. Mr. Feick holds a Bachelor of Science degree in Chemical Engineering from Queen’s University.

In connection with these appointments, Martin Burian and Jennifer Stubbs will be stepping down from the Board of Directors, effective May 1, 2026. The Company thanks Mr. Burian and Ms. Stubbs for their contributions and service and wishes them continued success in their future endeavours.

“On behalf of the Board, I would like to thank Martin and Jennifer for their contributions to Nanalysis and dedicated service to the Company and wish them continued success in their future endeavours.” said Sean Krakiwsky, Chief Executive Officer. “We are pleased to welcome Jonathan, Werner, and Steve. Their collective experience across instrumentation, global commercialization, and capital allocation will support the Company as we focus on scaling our core NMR platform and executing on our services growth strategy.”

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-board-transition-and-appointment-of-three-new-directors-302759750.html

SOURCE Nanalysis Scientific Corp.

Continue Reading

Technology

PCIS Emerges as Leading Risk and Claims Provider in Mid-Atlantic with Three Major Wins

Published

on

By

SEPTA, City of Baltimore, and Maryland Department of Transportation MTA adopt ClaimsVISION to modernize risk and claims operations

NEW YORK, May 1, 2026 /PRNewswire-PRWeb/ — PCIS, a leading provider of Risk & Claims Management Information System (RMIS), today announced a series of new and expanded client engagements across the Mid-Atlantic region, further solidifying its position as a trusted partner for transit agencies and public sector organizations.

“The biggest barrier to innovation in the public sector isn’t a lack of tools—it’s the weight of legacy data environments that were never built for real-time intelligence. You can’t layer AI on top of fragmented, batch-driven systems and expect results.

The Southeastern Pennsylvania Transportation Authority (SEPTA) has selected PCIS ClaimsVISION RMIS to enhance its risk management capabilities and support more efficient claims oversight. The City of Baltimore has chosen ClaimsVISION Claims and RMIS to modernize its claims administration and enterprise risk management operations. In addition, the Maryland Department of Transportation Maryland Transit Administration (MDOT MTA) has entered into a new five-year agreement with PCIS, extending a long-standing partnership and continuing its use of the ClaimsVISION platform.

These engagements reflect a broader trend among public entities seeking modern, configurable platforms to improve visibility, streamline workflows, and strengthen compliance across increasingly complex risk environments.

“The biggest barrier to innovation in the public sector isn’t a lack of tools—it’s the weight of legacy data environments that were never built for real-time intelligence. You can’t layer AI on top of fragmented, batch-driven systems and expect results. Organizations like SEPTA and Baltimore are rethinking the foundation—moving toward continuous, streaming data models that actually enable AI to deliver value”, said Michael Loizou, CSO of PCIS.

Across these implementations, PCIS will deliver a unified platform designed to:

Centralize claims and risk data for improved decision-makingEnhance BI and intelligent analytics capabilitiesStreamline workflows and reduce manual processesSupport regulatory compliance and audit readinessEnable scalable, configurable solutions tailored to public sector needs

The continued expansion of PCIS within the Mid-Atlantic region underscores the company’s growing presence among transit agencies and public entities seeking proven, purpose-built risk and claims management solutions.

Media Contact

Helene Quinn, PCIS, 1 2124051625, hquinn@pcisvision.com, www.pcisvision.com

View original content to download multimedia:https://www.prweb.com/releases/pcis-emerges-as-leading-risk-and-claims-provider-in-mid-atlantic-with-three-major-wins-302759785.html

SOURCE PCIS

Continue Reading

Technology

Private Equity’s AI Moment: The Greatest Value Lever in Decades — and the Hardest to Pull

Published

on

By

The following article is authored by Neil Dhar, Senior Vice President, IBM Consulting Americas

ARMONK, N.Y., May 1, 2026 /PRNewswire/ — Next week at Think 2026, we’ll outline the forces shaping the Enterprise AI Race, forces that apply with particular urgency to private equity. The organizations gaining ground today are not the ones betting on a single model. They are the ones redesigning how their businesses operate, building hybrid architectures that give them control, and deploying AI in ways that orchestrate value that compounds over time. 

The private equity industry understands this better than most. The days of pilots and promises are over, and the demand for hard proof (a.k.a. ROI) has begun. Is your revenue accelerating? Can you drive efficiency and profitability at the same time? What does long-term growth look like? These are the questions sitting across the table at every board meeting and investment committee, and the pressure is only intensifying.  

This pressure has forced major PE firms to move aggressively to formalize their AI strategies, including exploring joint ventures with leading LLM companies. They’re making a calculated bet on AI as the most powerful value‑creation lever the industry has seen in its history, and they recognize that the window to move is now. 

The logic is unmistakable. PE firms don’t run single businesses, they run portfolios. Which means AI playbooks that work don’t just transform one company; they compound across ten, twenty, fifty, hundreds. A workflow reinvented once becomes a repeatable asset. A governance framework built once becomes portfolio infrastructure. That multiplier effect is native to how PE creates value, and it’s what makes the intersection of private equity and enterprise AI one of the most consequential arenas in business right now. 

The bet is a no-brainer. Execution is where it gets hard.  

Here’s what we know to be true: competitive advantage won’t come from betting on a single LLM. It will come from building AI tailored to your business, shifting to a hybrid strategy that combines custom models, foundation models, and smaller specialized models, all grounded in an architecture that connects your data, your workflows, and your intelligence. In private equity, where the same playbook has to work across an entire portfolio, that distinction isn’t academic. It’s the difference between value that compounds and value that stalls. 

We know this because we lived it. We turned our own operations into the proving ground, analyzing nearly 400 operational workflows and deploying AI solutions across more than 100 so far, coupled with AI governance and enablement.

The result was $4.5B in productivity gains from AI, hybrid cloud, automation and consulting expertise, and proof of what works.

We then took that proof and productized those validated workflows into IBM Enterprise Advantage, a first-of-its-kind asset-based consulting service that enables clients to build and operate their own tailored internal AI platform at scale.

With digital workers, prebuilt tools, and native governance, clients have a headstart rather than a blank slate. And because it’s multi-model, they retain the freedom to shift as technology evolves. For private equity, that flexibility determines whether a company is an asset or a liability at exit. 

We’re bringing this same approach to private equity-backed companies, where the defining question is what changed and can you prove it.

A major U.S. telecommunications provider is deploying digital workers and prebuilt AI tools from Enterprise Advantage to accelerate the migration of more than 150 critical applications, delivering measurable savings within two quarters.Working with a leading insurance administrator, IBM is using agentic AI to overhaul end-to-end claims processing, a function where a single claim can involve dozens of tightly regulated steps across multiple systems. AI agents now read and structure claim documents, perform compliance checks, assess eligibility, and route cases automatically, resulting in faster cycle times, fewer bottlenecks, and an operating model built to scale. 

What private equity does here will ripple far beyond its own portfolios. When PE-backed companies deploy production-ready AI across the business, they reset competitive expectations for entire industries, forcing every competitor to respond. That is the Enterprise AI Race playing out in real time.

The choices made today will define portfolio performance for the next decade. Move too slowly and you’re handing the advantage to every competitor who didn’t. Move without discipline and you’re betting the portfolio on a foundation that hasn’t been proven. The firms that win will be the ones who understood that distinction early enough to do something about it.

About IBM 

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media contact: 

IBM
Lily O’Brien
lilyobrien@ibm.com

SOURCE IBM

Continue Reading

Trending